AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Craig-Hallum Analyst Maintains Buy Rating on Personalis with $7 Price Target
ByAinvest
Tuesday, Aug 12, 2025 1:38 am ET1min read
Personalis (PSNL) received a Buy rating and $7.00 price target from Craig-Hallum analyst John Wilkin. The company has a Strong Buy consensus and $6.89 price target, representing a 52.43% upside. PSNL's market cap is $399.9M and has a P/E ratio of -3.54. Corporate insider sentiment is negative, with 16 insiders selling shares over the past quarter.
Personalis Inc. (PSNL), a biotechnology company specializing in molecular diagnostics, reported its Q2 2025 earnings on August 5, 2025. The company posted a 23.8% year-over-year decline in revenue to $17.2 million and a slight improvement in per-share loss to $0.23, but net losses widened to $20.06 million. The company revised its 2025 revenue guidance to $70–$80 million from the previous $80–$90 million range, citing biopharma project delays and uncertainty around reimbursement timelines.Despite the revenue decline, analysts maintain a positive outlook on Personalis. HC Wainwright & Co. has maintained a "Buy" rating for Personalis but lowered its price target to $8.50 from $9.00 [1]. Analyst John Wilkin from Craig-Hallum also issued a "Buy" rating with a $7.00 price target [2]. Needham analyst Michael Matson maintained a "Buy" rating with a $7.00 price target, citing strong growth in the molecular testing segment and strategic focus on reimbursement for NeXT Personal products [3].
The company's CEO, Christopher M. Hall, highlighted strong clinical momentum with a 59% sequential clinical test volume growth and progress toward Medicare coverage for two indications by year-end. Gross margin was 27.6% for Q2, down from 35.6% year-over-year, with unreimbursed clinical test costs impacting margin by approximately 12% [1].
Personalis' corporate insider sentiment is negative, with 16 insiders selling shares over the past quarter. However, the company's market cap is $399.9 million, and its P/E ratio is -3.54. The Strong Buy consensus suggests a 52.43% upside to the current $6.89 price target [2].
References:
[1] https://www.ainvest.com/news/hc-wainwright-maintains-buy-rating-personalis-lowers-price-target-8-50-2508/
[2] https://www.tipranks.com/news/ratings/personalis-strong-molecular-testing-growth-and-strategic-mrd-focus-support-buy-rating-ratings
[3] https://www.quiverquant.com/news/PERSONALIS+Earnings+Results%3A+%24PSNL+Reports+Quarterly+Earnings
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet